Takeda

Seven pharma companies offer deprioritized compounds for re-purposing

Wednesday, July 23, 2014 10:15 AM

U.K. researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies.

More... »

WIRB Copernicus Group

Affymax to dissolve company

Thursday, June 26, 2014 01:52 PM

The board of directors of biopharmaceutical company Affymax has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all available cash to its stockholders.

More... »

CRF Health eCOA webinar series

Macrogenics, Takeda ink agreement for autoimmune disorders

Wednesday, May 28, 2014 01:04 PM

MacroGenics, a clinical-stage biopharmaceutical company discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, and Takeda Pharmaceutical have entered into an agreement for the development and commercialization of MGD010.

More... »

Annalisa Jenkins named IIR Partnerships’ Woman of the Year

Tuesday, April 1, 2014 01:43 PM

Annalisa Jenkins, former executive vice president, head of global R&D at Merck Serono, has been named IIR Partnerships’ Woman of the Year.

More... »

CEOi, NY Academy of Sciences to launch Global Alzheimer's Platform

Wednesday, February 26, 2014 01:21 PM

The Global CEO Initiative (CEOi) on Alzheimer's Disease and the New York Academy of Sciences have convened representatives from industry, academia, government and nonprofits to launch the development of a Global Alzheimer's Platform (GAP), designed to reduce the time and costs of Alzheimer's clinical trials, develop an infrastructure that promotes innovation and assure international collaboration.

More... »

NIH, industry and nonprofits join forces to speed validation of disease targets

Wednesday, February 5, 2014 01:02 PM

The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations have launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.

More... »

goBalto expands internationally

Monday, January 13, 2014 11:48 AM

goBalto, a provider of clinical study start-up solutions, has opened its first international locations, in Singapore and the U.K.

More... »

FutuRx begins operations in Israel

Monday, January 13, 2014 11:45 AM

FutuRx Incubator, formerly BioBoost, which has been granted a license by Israel's Ministry of Economy to establish a biotech incubator in Israel, began operations Jan. 1 at the Weizmann Science Park in Ness Ziona. Thirty to 40 startup companies are planned to be established during the next eight years. FutuRx was incorporated jointly by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development (JJDC) and Takeda Pharmaceutical through its corporate venture arm Takeda Ventures.

More... »

Takeda, Sunovion present positive data for Schizophrenia treatment

Tuesday, October 15, 2013 10:39 AM

With educational financial support provided by Takeda and Sunovion Pharmaceuticals Europe, new data has been presented which shows both short and long-term efficacy for lurasidone, an atypical antipsychotic treatment for schizophrenia. These data also showed lurasidone to have early separation from placebo, a rapid onset of action, a favorable side effect profile and to be a well-tolerated, efficacious option for patients with schizophrenia switching medication. Lurasidone has been approved in U.S., Canada and Switzerland and currently is under regulatory review in Europe.

More... »

Takeda terminates agreement with Immunomedics

Friday, October 11, 2013 02:17 PM

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, has received notification from Takeda Pharmaceutical of the termination of the licensing agreement signed between Nycomed and Immunomedics for the worldwide rights to veltuzumab, the humanized anti-CD20 antibody, for all non-cancer indications.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs